Table 3.

Reasons overall and risk rates by application type of disease-modifying treatment for discontinuation for three time periods 2010–2012, 2013–2015 and 2016–2018

Reasons for discontinuation, %	10–12	13–15	16–18
Antibodies/JCV-virus titre	1.28	1.85	1.51
family planning	4.10	5.48	6.34
Adverse events	5.13	15.89	13.12
Lack of effectiveness	18.21	19.31	27.90
Freedom of disease activity	NA	0.34	0.36
Non-medical reasons	71.28	57.11	50.76
Risk rates for discontinuation
Injectables	0.59	0.54	0.33
Orals	0.39	0.36	0.21
Infusions	0.59	0.37	0.17

Non-medical reasons summarise patients’ perceptions and wishes.

JCV, John Cunningham Virus; NA, not applicable as criteria was not captured.